Atorvastatin warnings and precautions: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Atorvastatin}}
{{CMG}} ; {{AE}} , {{PB}}
{{CMG}} ; {{AE}} , {{PB}}




Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment.  
Skeletal muscle effects (e.g., [[myopathy]] and [[rhabdomyolysis]]): Risks increase when higher doses are used concomitantly with [[cyclosporine]] and strong [[CYP3A4]] inhibitors (e.g., [[clarithromycin]], [[itraconazole]], HIV [[protease inhibitor]]s). Predisposing factors include advanced age (> 65), uncontrolled [[hypothyroidism]], and renal impairment.  


Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected.
Rare cases of [[rhabdomyolysis]] with [[acute renal failure]] secondary to [[myoglobinuria]] have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if [[myopathy]] is diagnosed or suspected.


Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.
Liver enzyme abnormalities: Persistent elevations in hepatic [[transaminase]]s can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.


A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs placebo.
A higher incidence of [[hemorrhagic stroke]] was seen in patients without [[CHD]] but with [[stroke]] or [[TIA]] within the previous 6 months in the LIPITOR 80 mg group vs placebo.

Revision as of 15:02, 30 January 2014

Atorvastatin
Lipitor® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: , Pratik Bahekar, MBBS [2]


Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment.

Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected.

Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.

A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs placebo.